Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 16 2024
0mins
Should l Buy LLY?
Source: NASDAQ.COM
Growth of Weight Loss Medications: The pharmaceutical industry is experiencing a surge in weight loss medications, particularly GLP-1 receptor agonists like Ozempic and Wegovy, driven by rising obesity rates and related health conditions. The global market for anti-obesity drugs is projected to reach $50 billion by 2030.
Emerging Competitors and Innovations: Companies such as Zealand Pharma and Viking Therapeutics are developing new weight loss treatments, including oral options and alternative hormone therapies, indicating a competitive landscape alongside established players Eli Lilly and Novo Nordisk.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1038.270
Low
950.00
Averages
1192
High
1500
Current: 1038.270
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's Innovation and Growth Prospects
- Strong Clinical Execution: Eli Lilly achieved positive outcomes in nearly all R&D key events in 2025, showcasing exceptional performance in diabetes and weight loss medications, which is expected to further drive market share and revenue growth in the future.
- Cancer Drug Progress: The company's cancer medication, Jaypirca, excelled in a phase 3 trial and is on track for label expansions, which will provide new revenue streams and enhance its competitiveness in oncology treatment.
- AI Investment: Eli Lilly is investing in building the industry's largest AI supercomputer to accelerate drug development, which is expected to significantly improve clinical trial success rates and bolster the company's innovative standing and market leadership in the pharmaceutical sector.
- Robust Financial Performance: The company continues to report strong financial results, boasts a rich product pipeline, and rewards shareholders through increasing dividends and share buybacks, demonstrating its diversified growth potential beyond diabetes and weight loss markets.
See More
Eli Lilly Reports Positive Results for Retevmo in NSCLC Trial
- Trial Success: The LIBRETTO-432 trial demonstrated that Retevmo (selpercatinib) as adjuvant therapy significantly improved event-free survival (EFS) in early-stage RET fusion-positive non-small cell lung cancer (NSCLC) patients, indicating its potential value and likely enhancing market acceptance.
- Survival Trends Favorable: Although overall survival results were immature at the time of analysis, preliminary data showed a favorable trend for Retevmo, highlighting its importance in early treatment and potentially encouraging more patients to undergo genomic testing for optimized therapy.
- Patient Recruitment: The LIBRETTO-432 trial enrolled 151 patients randomized 1:1 to receive either Retevmo or placebo, ensuring the reliability and clinical applicability of the results, further validating the use of targeted therapies in lung cancer.
- Future Outlook: Eli Lilly plans to present detailed trial results at an upcoming medical congress and submit data to global health authorities, which is expected to accelerate the adoption of targeted therapies in early-stage NSCLC patients and promote the widespread use of genomic testing.
See More
ELI LILLY - SELPERCATINIB SHOWED PROMISING OVERALL SURVIVAL TRENDS, BUT RESULTS REMAINED IMMATURE DUE TO LIMITED EVENTS AT THE TIME OF ANALYSIS
Overall Survival Results: The analysis indicates a trend in favor of Selpercatinib, suggesting improved overall survival rates for patients.
Immaturity of Analysis: The findings are considered immature due to the limited number of events observed during the analysis period.
See More
ELI LILLY'S PHASE 3 LIBRETTO-432 TRIAL ACHIEVES PRIMARY GOAL WITH ENHANCED EVENT-FREE SURVIVAL
Study Overview: The study focuses on Phase 3 of the Eli Lilly trial, which aims to evaluate the effectiveness of a new treatment.
Primary Endpoint: The primary endpoint of the study is to demonstrate improved event-free survival rates among participants.
See More
LILLY'S RETEVMO (SELPERCATINIB) PROVIDES SIGNIFICANT EVENT-FREE SURVIVAL ADVANTAGE AS ADJUVANT TREATMENT FOR EARLY-STAGE RET FUSION-POSITIVE LUNG CANCER
Event-Free Survival Benefit: A recent study highlights the substantial event-free survival benefit of using LILLY's RETEVMO (selpercatinib) as an early-stage therapy for patients with positive lung cancer mutations.
Adjunct Therapy: RETEVMO is positioned as an adjunct therapy, enhancing treatment options for patients diagnosed with early-stage RET fusion-positive lung cancer.
See More
Novo Nordisk's CagriSema Shows Promising Potential
- Intensifying Market Competition: Novo Nordisk faces fierce competition in the GLP-1 market from Eli Lilly, as Ozempic has been a key growth driver, but the company anticipates declining sales this year, highlighting the urgent need for next-generation therapies to regain market share.
- CagriSema Clinical Trial Success: CagriSema outperformed Wegovy in a phase 3 clinical trial for overweight or obese patients, achieving an average weight reduction of 22.7% after 68 weeks, indicating its potential in weight loss treatment and possibly providing a new growth avenue for Novo Nordisk.
- Regulatory Application Progress: Novo Nordisk has submitted regulatory applications for CagriSema as a weight loss treatment and plans to seek approval for the diabetes indication after completing two additional phase 3 studies, paving the way for future revenue growth.
- Manufacturing Complexity Challenges: Despite CagriSema's efficacy over Ozempic, its higher production costs and complexity compared to semaglutide, along with competition from Eli Lilly's retatrutide, may impact its market performance and overall business outlook.
See More
Eli Lilly's Innovation and Growth Prospects
- Strong Clinical Execution: Eli Lilly achieved positive outcomes in nearly all R&D key events in 2025, showcasing exceptional performance in diabetes and weight loss medications, which is expected to further drive market share and revenue growth in the future.
- Cancer Drug Progress: The company's cancer medication, Jaypirca, excelled in a phase 3 trial and is on track for label expansions, which will provide new revenue streams and enhance its competitiveness in oncology treatment.
- AI Investment: Eli Lilly is investing in building the industry's largest AI supercomputer to accelerate drug development, which is expected to significantly improve clinical trial success rates and bolster the company's innovative standing and market leadership in the pharmaceutical sector.
- Robust Financial Performance: The company continues to report strong financial results, boasts a rich product pipeline, and rewards shareholders through increasing dividends and share buybacks, demonstrating its diversified growth potential beyond diabetes and weight loss markets.
See More
Eli Lilly Reports Positive Results for Retevmo in NSCLC Trial
- Trial Success: The LIBRETTO-432 trial demonstrated that Retevmo (selpercatinib) as adjuvant therapy significantly improved event-free survival (EFS) in early-stage RET fusion-positive non-small cell lung cancer (NSCLC) patients, indicating its potential value and likely enhancing market acceptance.
- Survival Trends Favorable: Although overall survival results were immature at the time of analysis, preliminary data showed a favorable trend for Retevmo, highlighting its importance in early treatment and potentially encouraging more patients to undergo genomic testing for optimized therapy.
- Patient Recruitment: The LIBRETTO-432 trial enrolled 151 patients randomized 1:1 to receive either Retevmo or placebo, ensuring the reliability and clinical applicability of the results, further validating the use of targeted therapies in lung cancer.
- Future Outlook: Eli Lilly plans to present detailed trial results at an upcoming medical congress and submit data to global health authorities, which is expected to accelerate the adoption of targeted therapies in early-stage NSCLC patients and promote the widespread use of genomic testing.
See More
ELI LILLY - SELPERCATINIB SHOWED PROMISING OVERALL SURVIVAL TRENDS, BUT RESULTS REMAINED IMMATURE DUE TO LIMITED EVENTS AT THE TIME OF ANALYSIS
Overall Survival Results: The analysis indicates a trend in favor of Selpercatinib, suggesting improved overall survival rates for patients.
Immaturity of Analysis: The findings are considered immature due to the limited number of events observed during the analysis period.
See More
ELI LILLY'S PHASE 3 LIBRETTO-432 TRIAL ACHIEVES PRIMARY GOAL WITH ENHANCED EVENT-FREE SURVIVAL
Study Overview: The study focuses on Phase 3 of the Eli Lilly trial, which aims to evaluate the effectiveness of a new treatment.
Primary Endpoint: The primary endpoint of the study is to demonstrate improved event-free survival rates among participants.
See More
LILLY'S RETEVMO (SELPERCATINIB) PROVIDES SIGNIFICANT EVENT-FREE SURVIVAL ADVANTAGE AS ADJUVANT TREATMENT FOR EARLY-STAGE RET FUSION-POSITIVE LUNG CANCER
Event-Free Survival Benefit: A recent study highlights the substantial event-free survival benefit of using LILLY's RETEVMO (selpercatinib) as an early-stage therapy for patients with positive lung cancer mutations.
Adjunct Therapy: RETEVMO is positioned as an adjunct therapy, enhancing treatment options for patients diagnosed with early-stage RET fusion-positive lung cancer.
See More
Novo Nordisk's CagriSema Shows Promising Potential
- Intensifying Market Competition: Novo Nordisk faces fierce competition in the GLP-1 market from Eli Lilly, as Ozempic has been a key growth driver, but the company anticipates declining sales this year, highlighting the urgent need for next-generation therapies to regain market share.
- CagriSema Clinical Trial Success: CagriSema outperformed Wegovy in a phase 3 clinical trial for overweight or obese patients, achieving an average weight reduction of 22.7% after 68 weeks, indicating its potential in weight loss treatment and possibly providing a new growth avenue for Novo Nordisk.
- Regulatory Application Progress: Novo Nordisk has submitted regulatory applications for CagriSema as a weight loss treatment and plans to seek approval for the diabetes indication after completing two additional phase 3 studies, paving the way for future revenue growth.
- Manufacturing Complexity Challenges: Despite CagriSema's efficacy over Ozempic, its higher production costs and complexity compared to semaglutide, along with competition from Eli Lilly's retatrutide, may impact its market performance and overall business outlook.
See More
